Trial Profile

Phase II/III study of M606102 in the treatment of axillary hyperhidrosis

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 04 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glycopyrrolate (Primary)
Indications Hyperhidrosis
Focus Registrational; Therapeutic Use
Sponsors Maruho

Most Recent Events

11 Feb 2022 According to a Journey Medical Corporation media release, the Maruho has received approval from the apan's Ministry of Health, Labor and Welfare ("MHLW") for Rapifort Wipes 2.5% (glycopyrronium tosylate hydrate) for the treatment of primary axillary hyperhidrosis. This approval triggers a milestone payment of $10 million to Journey Medical, $7.5 million of which will be paid to Dermira.
19 Jan 2022 New trial record
01 Jan 2022 Primary endpoint (proportion of patients achieving a HDSS 2-point improvement) has been met, as per Results published in the Journal of Dermatology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com